Clinical support for muscle regeneration

Ystem moves its origin from a strictly close contact between academic and clinical environment.

Its scientific board boasts previous important experiences in designing clinical studies: in 2002, Dr Yvan Torrente coordinated the first phase-I clinical trial for the in vivo validation of autologous muscle-derived stem cells transplantation in Duchenne Muscular Dystrophy; in 2010, a single patient was treated with a combination of scaffold and skin derived stem cells for the partial nerve motor and sensor restoration; in the same year, another clinical trial, involving mesoangioblasts infusion, was implemented as possible therapy for Duchenne muscular dystrophy; in 2011, an autograft using bone marrow stem cells for facioscapulohumeral muscular dystrophy has been made up.

The company is therefore featured with the expertise and all the skills for planning and developing clinical studies, which do not merely guarantee safety reliability, but also follow-up observation.